ABSTRACT
We aimed to investigate the link between serum metabolites, gut bacterial community composition, and clinical variables in Parkinson’s disease (PD) and healthy control subjects (HC). 139 metabolite features were found to be differentially abundant between the PD and Control groups. No associations were found between metabolite features and within-PD clinical variables. The results suggest alterations in serum metabolite profiles in PD, and the results of correlation analysis between metabolite features and microbiota suggest that several bacterial taxa are associated with altered lipid and energy metabolism in PD.
Competing Interest Statement
PABP, LP, PA, and FS have patents issued (FI127671B & US10139408B2) and pending (US16/186,663 & EP3149205) that are assigned to NeuroBiome Ltd.
FS is founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd., is a member of the scientific advisory board and has received consulting fees and stock options from Axial Biotherapeutics.
Funding Statement
This study was funded by the Michael J. Fox Foundation for Parkinsons Research, the Academy of Finland (295724, 310835), the Finnish Medical Foundation, and the Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, TYH2018224, TYH2020335).
DKT thanks Michael J Fox Foundation and Parkinsons UK for supporting research leading to contribution to this work, and Prof Perdita Barran for her invaluable input throughout this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa. All participants gave informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses of all authors: pedro.pereira{at}helsinki.fi; drupad.trivedi{at}manchester.ac.uk; justin.silverman{at}duke.edu; ilhan.duru{at}helsinki.fi; lars.paulin{at}helsinki.fi; petri.auvinen{at}helsinki.fi; filip.scheperjans{at}hus.fi
Data Availability
The 16S rRNA gene sequence abundance raw data is available from Aho et al. (2019)9. The metabolomics data will be hosted on MetaboLights (https://www.ebi.ac.uk/metabolights/index) and also on The University of Manchester servers. It will also be made available upon reasonable request. The clinical data is also available upon request due to European subject confidentiality laws.